Identification of Bacterial Metabolites Modulating Breast Cancer Cell Proliferation and Epithelial-Mesenchymal Transition
Breast cancer patients are characterized by the oncobiotic transformation of multiple microbiome communities, including the gut microbiome. Oncobiotic transformation of the gut microbiome impairs the production of antineoplastic bacterial metabolites. The goal of this study was to identify bacterial metabolites with antineoplastic properties. We constructed a 30-member bacterial metabolite library and screened the library compounds for effects on cell proliferation and epithelial-mesenchymal transition. The metabolites were applied to 4T1 murine breast cancer cells in concentrations corresponding to the reference serum concentrations. However, yric acid, glycolic acid, d-mannitol, 2,3-butanediol, and trans-ferulic acid exerted cytostatic effects, and 3-hydroxyphenylacetic acid, 4-hydroxybenzoic acid, and vanillic acid exerted hyperproliferative effects. Furthermore, 3-hydroxyphenylacetic acid, 4-hydroxybenzoic acid, 2,3-butanediol, and hydrocinnamic acid inhibited epithelial-to-mesenchymal (EMT) transition. We identified redox sets among the metabolites (d-mannitol-d-mannose, 1-butanol-butyric acid, ethylene glycol-glycolic acid-oxalic acid), wherein only one partner within the set (d-mannitol, butyric acid, glycolic acid) possessed bioactivity in our system, suggesting that changes to the local redox potential may affect the bacterial secretome. Of the nine bioactive metabolites, 2,3-butanediol was the only compound with both cytostatic and anti-EMT properties.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:28 |
|---|---|
| Enthalten in: |
Molecules (Basel, Switzerland) - 28(2023), 15 vom: 05. Aug. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Ujlaki, Gyula [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 14.08.2023 Date Revised 14.08.2023 published: Electronic Citation Status MEDLINE |
|---|
| doi: |
10.3390/molecules28155898 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM360703747 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM360703747 | ||
| 003 | DE-627 | ||
| 005 | 20231226083557.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3390/molecules28155898 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1202.xml |
| 035 | |a (DE-627)NLM360703747 | ||
| 035 | |a (NLM)37570868 | ||
| 035 | |a (PII)5898 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Ujlaki, Gyula |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Identification of Bacterial Metabolites Modulating Breast Cancer Cell Proliferation and Epithelial-Mesenchymal Transition |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 14.08.2023 | ||
| 500 | |a Date Revised 14.08.2023 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Breast cancer patients are characterized by the oncobiotic transformation of multiple microbiome communities, including the gut microbiome. Oncobiotic transformation of the gut microbiome impairs the production of antineoplastic bacterial metabolites. The goal of this study was to identify bacterial metabolites with antineoplastic properties. We constructed a 30-member bacterial metabolite library and screened the library compounds for effects on cell proliferation and epithelial-mesenchymal transition. The metabolites were applied to 4T1 murine breast cancer cells in concentrations corresponding to the reference serum concentrations. However, yric acid, glycolic acid, d-mannitol, 2,3-butanediol, and trans-ferulic acid exerted cytostatic effects, and 3-hydroxyphenylacetic acid, 4-hydroxybenzoic acid, and vanillic acid exerted hyperproliferative effects. Furthermore, 3-hydroxyphenylacetic acid, 4-hydroxybenzoic acid, 2,3-butanediol, and hydrocinnamic acid inhibited epithelial-to-mesenchymal (EMT) transition. We identified redox sets among the metabolites (d-mannitol-d-mannose, 1-butanol-butyric acid, ethylene glycol-glycolic acid-oxalic acid), wherein only one partner within the set (d-mannitol, butyric acid, glycolic acid) possessed bioactivity in our system, suggesting that changes to the local redox potential may affect the bacterial secretome. Of the nine bioactive metabolites, 2,3-butanediol was the only compound with both cytostatic and anti-EMT properties | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a 2,3-butanediol | |
| 650 | 4 | |a 3-hydroxyphenylacetic acid | |
| 650 | 4 | |a 4-hydroxybenzoic acid | |
| 650 | 4 | |a bacterial metabolite | |
| 650 | 4 | |a breast cancer | |
| 650 | 4 | |a butyric acid | |
| 650 | 4 | |a d-mannitol | |
| 650 | 4 | |a dysbiosis | |
| 650 | 4 | |a epithelial-mesenchymal transition | |
| 650 | 4 | |a glycolic acid | |
| 650 | 4 | |a high content screening | |
| 650 | 4 | |a hydrocinnamic acid | |
| 650 | 4 | |a metabolite signaling | |
| 650 | 4 | |a microbiome | |
| 650 | 4 | |a proliferation | |
| 650 | 4 | |a secretome | |
| 650 | 4 | |a trans-ferulic acid | |
| 650 | 4 | |a vanillic acid | |
| 650 | 7 | |a glycolic acid |2 NLM | |
| 650 | 7 | |a 0WT12SX38S |2 NLM | |
| 650 | 7 | |a 2,3-butylene glycol |2 NLM | |
| 650 | 7 | |a 45427ZB5IJ |2 NLM | |
| 650 | 7 | |a 3-hydroxybenzeneacetic acid |2 NLM | |
| 650 | 7 | |a K59Z6Z8REF |2 NLM | |
| 650 | 7 | |a 4-hydroxybenzoic acid |2 NLM | |
| 650 | 7 | |a JG8Z55Y12H |2 NLM | |
| 650 | 7 | |a Cytostatic Agents |2 NLM | |
| 650 | 7 | |a Butyric Acid |2 NLM | |
| 650 | 7 | |a 107-92-6 |2 NLM | |
| 650 | 7 | |a Antineoplastic Agents |2 NLM | |
| 700 | 1 | |a Kovács, Tünde |e verfasserin |4 aut | |
| 700 | 1 | |a Vida, András |e verfasserin |4 aut | |
| 700 | 1 | |a Kókai, Endre |e verfasserin |4 aut | |
| 700 | 1 | |a Rauch, Boglára |e verfasserin |4 aut | |
| 700 | 1 | |a Schwarcz, Szandra |e verfasserin |4 aut | |
| 700 | 1 | |a Mikó, Edit |e verfasserin |4 aut | |
| 700 | 1 | |a Janka, Eszter |e verfasserin |4 aut | |
| 700 | 1 | |a Sipos, Adrienn |e verfasserin |4 aut | |
| 700 | 1 | |a Hegedűs, Csaba |e verfasserin |4 aut | |
| 700 | 1 | |a Uray, Karen |e verfasserin |4 aut | |
| 700 | 1 | |a Nagy, Péter |e verfasserin |4 aut | |
| 700 | 1 | |a Bai, Peter |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Molecules (Basel, Switzerland) |d 2004 |g 28(2023), 15 vom: 05. Aug. |w (DE-627)NLM172073448 |x 1420-3049 |7 nnns |
| 773 | 1 | 8 | |g volume:28 |g year:2023 |g number:15 |g day:05 |g month:08 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3390/molecules28155898 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 28 |j 2023 |e 15 |b 05 |c 08 | ||